Loading
The 1987 study showing that people who lack the Lewis blood group antigens cannot make the CA 19-9 tumour marker, so in about one patient in ten a normal blood test says nothing about the cancer.
Tempero and colleagues studied 20 pancreatic cancer patients: Lewis a and b phenotype in saliva or on red cells, serum CA 19-9 by radioimmunoassay, and CA 19-9 and Lewis antigen expression in tumour tissue by immunoperoxidase. Patients who were Lewis a-negative b-negative failed to express CA 19-9 in tumour tissue and had normal or low serum levels (below 37 units per millilitre; P = 0.0011 versus Lewis-positive patients), whereas 88 percent of Lewis a-positive or b-positive patients had raised serum CA 19-9. The authors concluded that Lewis-negative patients cannot manufacture CA 19-9, and noted that Lewis a-positive patients unexpectedly expressed Lewis b antigen in tumour tissue.
The reason a normal CA 19-9 never rules pancreatic cancer out, why Lewis-negative patients need a different marker (CA 125, CEA or CA 19-9-independent panels), and a constraint on every blood-based detection idea on this page.
Shares Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection, Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.